There is no single age when every man should start prostate cancer screening. For men at average risk, major urology guidelines generally begin the screening discussion between ages 45 and 50. Men with higher-risk features—including Black or African ancestry, a strong family history or certain inherited cancer-risk mutations—may need to begin earlier, often between ages 40 and 45. The decision should also consider life expectancy, overall health and personal preferences.
01. When Should Men Start Prostate Cancer Screening?
What age should an average-risk man first discuss PSA screening?
For a healthy man without a strong family history, known high-risk genetic variant or another major risk factor, the most defensible starting window is approximately 45–50 years.
That range reflects differences between major professional guidelines rather than a disagreement that one exact birthday is biologically correct.
| Guideline / organization | Average-risk starting approach | Important qualification |
|---|---|---|
| AUA/SUO | A baseline PSA may be offered between ages 45–50. | Regular screening is strongly supported at ages 50–69, generally every 2–4 years, with individualization. |
| EAU | Offer early PSA testing from age 50. | Applies to well-informed men at appropriate life expectancy; high-risk men start earlier. |
| American Cancer Society | Discuss screening from age 50 for average-risk men expected to live at least 10 more years. | Testing follows an informed discussion of possible benefits and harms. |
| USPSTF | Its current final recommendation focuses shared decision-making on ages 55–69. | The 2018 recommendation is currently being updated; it recommends against routine PSA screening at age 70 and older. |
Is prostate cancer screening the same as testing a man who has symptoms?
No.
Screening means testing a person who does not have symptoms or known prostate cancer in an attempt to detect clinically important disease before it causes problems.
A man with:
- an abnormal prostate examination;
- blood in the urine;
- unexplained bone pain;
- new neurological symptoms;
- or another finding that raises clinical concern
may need a diagnostic evaluation rather than routine age-based screening.
Likewise, men who have already been treated for prostate cancer are undergoing surveillance rather than screening. That distinction is explained in PSA After Prostatectomy.
Is PSA the first screening test?
Yes.
Current AUA/SUO guidance recommends PSA as the first screening test for prostate cancer.
A digital rectal examination may sometimes add information, particularly after an elevated PSA, but current AUA guidance does not recommend DRE as a stand-alone screening method.
The purpose of screening is also no longer simply to detect as many prostate cancers as possible.
The modern goal is to identify cancers likely to threaten health while reducing unnecessary detection and treatment of low-risk disease.
02. Who Should Consider Starting PSA Screening Earlier?
How does family history change the starting age?
Family history can materially increase prostate-cancer risk, especially when:
- a father, brother or son developed prostate cancer;
- the relative was diagnosed at a younger age;
- multiple relatives are affected;
- prostate cancer caused death in a close relative;
- or prostate cancer occurs alongside a broader hereditary pattern of breast, ovarian, pancreatic or other cancers.
Current AUA/SUO guidance recommends offering screening at approximately 40–45 years to people with a strong family history.
Current EAU guidance recommends PSA testing from 45 years for men with a family history of prostate cancer diagnosed before age 60.
Why can Black or African-ancestry men be offered screening earlier?
Population studies show that men of African ancestry, particularly in Western populations, have a higher incidence of prostate cancer and a greater burden of advanced or lethal disease.
Current AUA/SUO guidance lists Black ancestry among the factors supporting screening from age 40–45.
Current EAU guidance recommends offering early PSA testing from age 45 to men of African descent.
This is a population-level risk association.
It does not mean ancestry alone determines an individual man’s cancer biology. Genetics, access to healthcare, environmental exposures, socioeconomic factors and other influences also contribute to observed differences in outcomes.
What inherited mutations can justify earlier screening?
Inherited cancer-risk variants can shift screening earlier.
The clearest prostate-cancer screening evidence currently exists for BRCA2.
EAU guidance recommends PSA testing from age 40 for men carrying a BRCA2 mutation.
AUA/SUO guidance more broadly recommends screening from age 40–45 in people with relevant germline mutations.
Other inherited syndromes—including BRCA1 and mismatch-repair gene variants associated with Lynch syndrome—may also increase prostate-cancer risk, although the strength of evidence and recommended surveillance strategies differ by gene.
Does one relative with prostate cancer automatically mean screening at 40?
No.
The term strong family history matters.
Risk is generally more concerning when:
- several close relatives are affected;
- diagnoses occurred at younger ages;
- relatives developed metastatic disease;
- or prostate cancer caused death.
The next guide examines family history in more detail and explains how the number and age of affected relatives change prostate-cancer risk.
03. What Should Be Discussed Before Starting PSA Screening?
What does shared decision-making mean?
Shared decision-making means that screening is not simply ordered because a patient reached a particular age.
The clinician and patient discuss:
- the man’s estimated prostate-cancer risk;
- the possibility of detecting clinically significant cancer early;
- the chance of a false-positive or temporarily elevated PSA;
- what additional testing may follow an abnormal result;
- the possibility of finding a low-risk cancer that never would have caused symptoms;
- potential treatment effects;
- life expectancy and competing health problems;
- and how the patient personally values those trade-offs.
Current AUA/SUO guidance treats prostate-cancer screening as a preference-sensitive decision and strongly emphasizes shared decision-making.
What is the possible benefit of PSA screening?
The main goal is to identify clinically significant localized prostate cancer while it can still potentially be cured.
Large randomized European screening trials show that appropriately organized PSA-based screening can reduce the risk of metastatic prostate cancer and prostate-cancer death.
Current AUA guidance cites randomized evidence supporting regular screening at ages 50–69.
The benefit, however, is not immediate.
It generally takes many years for reduced prostate-cancer mortality to emerge, which is why life expectancy is central to the decision.
What are the possible harms?
An elevated PSA is not a cancer diagnosis.
PSA can increase because of:
- benign prostate enlargement;
- prostatitis or urinary infection;
- recent ejaculation;
- urinary retention;
- recent prostate procedures;
- biological variation;
- and prostate cancer.
An abnormal screening result can therefore lead to:
- repeat blood testing;
- additional biomarkers;
- prostate MRI;
- biopsy;
- anxiety;
- and sometimes detection of a cancer that might never have harmed the patient.
Does an elevated screening PSA automatically mean biopsy?
No.
Modern prostate evaluation usually contains several steps before biopsy.
For a newly elevated PSA, current AUA/SUO guidance recommends repeating the PSA before proceeding to another biomarker, imaging or biopsy.
Current EAU guidance similarly recommends repeating a newly elevated PSA in appropriate asymptomatic men.
If the elevation persists, subsequent assessment may use:
- age and family history;
- digital rectal examination;
- percent-free PSA or another biomarker;
- prostate volume;
- PSA density;
- validated risk calculators;
- and prostate MRI.
This risk-stratified pathway is designed to reduce unnecessary biopsy while still identifying clinically significant cancer.
04. How Often Should PSA Screening Be Repeated and When Should It Stop?
Does every man need a PSA test every year?
No.
Annual screening is not automatically necessary for every man.
Current AUA/SUO guidance recommends regular screening every two to four years for people aged approximately 50–69, while allowing the interval to be personalized according to:
- age;
- baseline PSA;
- prostate-cancer risk;
- life expectancy;
- general health;
- and personal preference.
AUA evidence suggests that for men aged approximately 45–70:
- PSA between about 1 and 3 ng/mL can support a repeat interval of roughly 1–4 years;
- and PSA below 1 ng/mL or below the age-specific median may justify a longer interval in otherwise lower-risk men.
Can a baseline PSA determine future screening frequency?
Yes.
One of the most important developments in modern screening is using the first PSA to estimate long-term risk rather than testing everyone at the same interval.
Current EAU guidance recommends a risk-adapted strategy based partly on the initial PSA.
Men considered initially at greater risk include:
- those with PSA above approximately 1 ng/mL at age 40;
- and those with PSA above approximately 2 ng/mL at age 60.
EAU guidance suggests follow-up approximately every two years for these higher baseline PSA groups while allowing intervals of up to eight years in lower-risk men.
At what age should prostate cancer screening stop?
There is no universal stop age either.
The decision shifts from chronological age toward life expectancy and health status.
Current EAU guidance strongly recommends stopping early detection when life expectancy is below approximately 15 years, because men in this situation are unlikely to benefit from screening.
The American Cancer Society frames screening discussions around men expected to live at least approximately 10 more years.
AUA/SUO guidance recommends personalizing or discontinuing screening according to:
- age;
- PSA;
- risk;
- life expectancy;
- overall health;
- and patient preference.
The currently finalized USPSTF recommendation advises against routine PSA-based screening at age 70 and older, although that 2018 recommendation is undergoing an update.
Can screening stop earlier when PSA is very low?
Potentially.
Long-term cohort data suggest that men around age 60 with very low PSA have a very small lifetime risk of dying from prostate cancer.
Current AUA/SUO guidance therefore supports individualized discontinuation or substantially lengthened screening intervals in appropriate lower-risk men.
This should still account for strong family history or known inherited risk.
Prostate Cancer Screening Age at a Glance
| Question | Practical answer |
|---|---|
| Is there one prostate cancer screening age for every man? | No. Screening age should be risk-adapted. |
| When can average-risk men start discussing PSA? | Generally around ages 45–50, depending on the guideline and individual risk. |
| What does AUA/SUO recommend for average risk? | A baseline PSA may be offered between ages 45–50. |
| What does the EAU recommend for average risk? | Offer early PSA testing from age 50 to well-informed men with sufficient life expectancy. |
| What does the American Cancer Society recommend? | Discuss screening from age 50 for average-risk men expected to live at least 10 more years. |
| When should higher-risk men start? | Often between ages 40–45. |
| When should Black or African-ancestry men start? | AUA/SUO recommends offering screening at 40–45 for increased risk; EAU recommends early testing from 45 for African descent. |
| When should men with a strong family history start? | Usually around ages 40–45, depending on the strength and pattern of family history. |
| When should BRCA2 carriers start? | EAU recommends early PSA testing from age 40. |
| Is PSA the first screening test? | Yes. AUA/SUO recommends PSA as the first-line screening test. |
| Is DRE enough by itself? | No. Current AUA guidance does not recommend DRE as a stand-alone screening test. |
| Does one elevated PSA mean cancer? | No. |
| Should a newly elevated PSA be repeated? | Yes, in appropriate patients before secondary biomarkers, MRI or biopsy. |
| Does every man need annual PSA testing? | No. |
| How often does AUA/SUO recommend regular screening at ages 50–69? | Generally every 2–4 years, with personalization. |
| Can a low baseline PSA justify less frequent testing? | Yes. |
| When should screening stop? | It should be individualized according to age, health, PSA, risk, life expectancy and patient preference. |
| What does the EAU say about life expectancy? | Men with less than approximately 15 years of life expectancy are unlikely to benefit from early detection. |
| Does the ACS use a life-expectancy threshold? | Its screening discussion applies to men expected to live at least about 10 more years. |
| What does the current USPSTF recommendation say? | Individual decision-making at ages 55–69 and no routine PSA screening at age 70 or older; the recommendation is currently being updated. |
Summary
- There is no single prostate-cancer screening age that applies to every man.
- Screening age should be based on prostate-cancer risk, general health, life expectancy and patient preference.
- Current AUA/SUO guidance allows a baseline PSA between ages 45 and 50 for average-risk people.
- Current EAU guidance recommends early PSA testing from age 50 for average-risk men.
- The American Cancer Society recommends discussing screening from age 50 for average-risk men expected to live at least 10 more years.
- AUA/SUO recommends offering screening from ages 40–45 to people at increased risk.
- AUA increased-risk factors include Black ancestry, strong family history and relevant germline mutations.
- EAU recommends early PSA testing from age 45 for men of African descent.
- EAU also recommends testing from age 45 when there is a family history of prostate cancer diagnosed before age 60.
- EAU recommends early PSA testing from age 40 for BRCA2 carriers.
- Family history should be evaluated by the number of affected relatives, age at diagnosis and disease aggressiveness—not simply as yes or no.
- PSA is the recommended first-line screening test in current AUA/SUO guidance.
- DRE should not be used as the sole screening method.
- Screening is different from diagnostic testing prompted by symptoms or abnormal clinical findings.
- The goal of screening is to find clinically significant prostate cancer early enough for potentially curative treatment.
- PSA screening can also produce false-positive results and unnecessary downstream testing.
- Overdiagnosis refers to finding a prostate cancer that would never have caused symptoms or shortened life.
- Shared decision-making should include both possible benefits and harms.
- A newly elevated PSA should generally be confirmed before immediately proceeding to MRI, biomarkers or biopsy.
- Screening intervals do not need to be identical for every man.
- AUA/SUO recommends regular screening every two to four years for people aged approximately 50–69.
- Baseline PSA can be used to personalize future screening intervals.
- Men with low PSA and otherwise low risk can often be screened less frequently.
- Men at higher inherited or clinical risk may need shorter intervals.
- There is no universal age when every man should stop screening.
- Current EAU guidance recommends stopping early detection when life expectancy is below approximately 15 years.
- The American Cancer Society uses an expected life span of at least approximately 10 years when considering screening discussions.
- AUA/SUO recommends personalizing discontinuation according to age, PSA, risk, health, life expectancy and preference.
- The current USPSTF final recommendation uses individual decision-making for ages 55–69 and recommends against routine PSA screening from age 70; this recommendation is currently being updated.
Educational disclaimer: This article provides general medical education about PSA-based prostate cancer screening. Screening recommendations vary between professional organizations and should be adapted to personal risk, family history, ancestry, inherited genetic variants, prior PSA values, overall health and life expectancy. A screening PSA does not diagnose prostate cancer, and an elevated result should be interpreted through an appropriate clinical pathway rather than in isolation.
Explore the PSA Pathway
For the overall PSA testing and early-detection framework, see PSA Testing and Prostate Screening.
For what the screening blood test measures, see What Is PSA?.
For how PSA values are interpreted in context, see What Is a Normal PSA Level? and PSA Levels by Age.
For why an elevated screening result does not automatically mean prostate cancer, see Can PSA Be High Without Prostate Cancer?.
For PSA adjusted for prostate volume, see What Is PSA Density?.
The next guide explains how family history changes prostate-cancer risk and when a father, brother or multiple affected relatives may justify earlier PSA screening.
Evidence Sources
- European Association of Urology. Prostate Cancer Guidelines — Individual Early Detection, Risk-Adapted PSA Testing and Screening Ages.
- American Urological Association / Society of Urologic Oncology. Early Detection of Prostate Cancer Guideline Part I — Prostate Cancer Screening.
- Lin DW, et al. Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline. Journal of Urology. 2026.
- American Cancer Society. Guidelines for Prostate Cancer Early Detection.
- American Cancer Society. Prostate Cancer Risk Factors — Age, Family History, Ancestry and Inherited Gene Changes.
- U.S. Preventive Services Task Force. Prostate Cancer Screening Recommendation — Current Final Statement and Update Status.
